| 85.49 1.47 (1.75%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 118.83 | 1-year : | 132.89 |
| Resists | First : | 101.74 | Second : | 113.77 |
| Pivot price | 91.9  |
|||
| Supports | First : | 82.26 | Second : | 68.44 |
| MAs | MA(5) : | 87.84 |
MA(20) : | 95.36 |
| MA(100) : | 99.75  |
MA(250) : | 70.2 |
|
| MACD | MACD : | -5 |
Signal : | -4.2 |
| %K %D | K(14,3) : | 7.4 |
D(3) : | 6.8 |
| RSI | RSI(14): 29.9 |
|||
| 52-week | High : | 120.73 | Low : | 36.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GH ] has closed above bottom band by 5.6%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.31 - 88.84 | 88.84 - 89.35 |
| Low: | 83.53 - 84.15 | 84.15 - 84.74 |
| Close: | 84.55 - 85.45 | 85.45 - 86.32 |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Fri, 13 Mar 2026
Colonoscopies worry many Americans, who favor a blood test for colon cancer - Stock Titan
Wed, 11 Mar 2026
GH: First-of-its-kind monitoring CDx and rapid Shield adoption fuel strong growth outlook - TradingView
Tue, 10 Mar 2026
GH: Quest partnership and new guidelines drive Shield and Guardant360 growth, boosting revenue outlook - TradingView
Tue, 10 Mar 2026
Colon cancer blood test rolls out nationwide through Quest Diagnostics - Stock Titan
Tue, 10 Mar 2026
Hidalgo Medina sells Guardant Health (GH) shares for $118,996 - Investing.com
Mon, 09 Mar 2026
Guardant Health (GH) director sells 1,300 shares after option exercise - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 131 (M) |
| Shares Float | 126 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 101.1 (%) |
| Shares Short | 10,520 (K) |
| Shares Short P.Month | 9,800 (K) |
| EPS | -3.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.76 |
| Profit Margin | -42.4 % |
| Operating Margin | -43 % |
| Return on Assets (ttm) | -15.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 39.4 % |
| Gross Profit (p.s.) | 4.82 |
| Sales Per Share | 7.48 |
| EBITDA (p.s.) | -3.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -185 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | -25.75 |
| PEG Ratio | 0 |
| Price to Book value | -112.49 |
| Price to Sales | 11.41 |
| Price to Cash Flow | -60.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|